文献速递造血干细胞移植与细胞治疗浆细胞疾病

普萘洛尔抑制自体造血干细胞移植受者的分子风险标志物:一项2期随机对照生物标志物试验

Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.
PubMed 文献 · Blood Adv · 2020-01-01

这项2期随机对照生物标志物试验在25例接受自体造血干细胞移植的多发性骨髓瘤患者中,检验非选择性β受体阻滞剂普萘洛尔对CTRA相关基因表达的影响。普萘洛尔从移植前1周至移植后4周给药。意向性分析显示,普萘洛尔组CTRA基因表达和CD16-经典单核细胞活化均较对照组下降更明显,CD34+细胞相关基因转录相对上调,CD33+髓系祖细胞相关基因转录相对下调。

要点

  • 普萘洛尔可降低HCT受者CTRA相关基因表达及CD16-经典单核细胞活化。
  • 普萘洛尔组CD34+细胞相关基因转录相对上调,CD33+髓系祖细胞相关基因转录相对下调。
  • 普萘洛尔组有植入加速和移植后感染减少的非显著趋势。

核心结论

  • 围HCT期使用普萘洛尔可抑制与不良结局相关的细胞和分子通路,使其成为癌症相关HCT的潜在辅助治疗候选药物。

研究设计与样本

  • 普萘洛尔在HCT前1周至HCT后4周给药,于基线、第-2天和第+28天采血。
  • 意向性分析控制人口学特征、高危疾病(国际骨髓瘤工作组风险评分)和肿瘤分期。

主要发现

  • 与对照组相比,普萘洛尔组从基线至HCT第-2天和第+28天CTRA基因表达下降更明显(P = .017)。
  • 普萘洛尔组CD16-经典单核细胞活化的生物信息学指标下降更明显(P = .005)。
  • 普萘洛尔组CD34+细胞相关基因转录相对上调(P = .011)。
  • 普萘洛尔组CD33+髓系祖细胞相关基因转录相对下调(P = .001)。
  • 辅助分析发现普萘洛尔组有植入加速和移植后感染减少的非显著趋势。

关键数值与推荐

  • 主要分析指标为53基因CTRA指示谱及外周血单核细胞中CTRA相关细胞过程的测量。

临床怎么用

  • 普萘洛尔可能作为癌症相关HCT的辅助治疗,但需进一步研究确认其临床获益。

局限性

  • 样本量小(共25例),为2期生物标志物试验。
  • 植入加速和感染减少仅为非显著趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preclinical research shows that stress-induced activation of the sympathetic nervous system can promote hematopoietic malignancies via β-adrenoreceptor-mediated molecular pathways. Hematopoietic cell transplant (HCT) recipients exposed to conditions of chronic stress show activation of a conserved transcriptional response to adversity (CTRA) gene expression profile, which in turn is associated with increased relapse and decreased disease-free survival. We conducted a randomized controlled phase 2 biomarker trial testing the impact of the nonselective β-antagonist propranolol on CTRA-related gene expression of 25 individuals receiving an autologous HCT for multiple myeloma. Propranolol was administered for 1 week prior to and 4 weeks following HCT. Blood was collected at baseline, day -2, and day +28. Intention-to-treat analyses controlling for demographic characteristics, high-risk disease (International Myeloma Working Group risk score), and tumor stage tested effects on a 53-gene CTRA indicator profile and measures of CTRA-related cellular processes in peripheral blood mononuclear cells. Twelve participants were randomized to the intervention and 13 to the control. Relative to the control group, propranolol-treated patients showed greater decreases from baseline to HCT day -2 and day +28 for both CTRA gene expression (P = .017) and bioinformatic measures of CD16- classical monocyte activation (P = .005). Propranolol-treated patients also showed relative upregulation of CD34+ cell-associated gene transcripts (P = .011) and relative downregulation of myeloid progenitor-containing CD33+ cell-associated gene transcripts (P = .001). Ancillary analyses identified nonsignificant trends toward accelerated engraftment and reduced posttransplant infections in propranolol-treated patients. Peri-HCT propranolol inhibits cellular and molecular pathways associated with adverse outcomes. Changes in these pathways make propranolol a potential candidate for adjunctive therapy in cancer-related HCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Knight JM, Rizzo JD, Hari P, et al. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020. PMID: 32027744. doi:10.1182/bloodadvances.2019000765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。